1. 1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada
Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT
S. Berry,1 E. Van Cutsem, A. Kretzschmar, M. Michael, F. Rivera, M. DiBartolomeo, M. Mazier, N. Andre, D. Cunningham, on behalf of the BEAT investigators
1 Sunnybrook Odette Cancer Centre,
University of Toronto, Canada
S. Berry

2. First BEAT: study overview
First-line metastatic CRC (1,965)
Bevacizumab + standard chemotherapy PD
Bevacizumab: 5mg/kg every 2 weeks or 7.5mg/kg every 3 weeks
Chemotherapy at physician’s discretion
Endpoints: safety and efficacy
First patient enrolled June 2004, enrolment completed February 2006
At follow-up 1 February 2008, data available for 1,914 patients
Median follow-up 21.1 months
S. Berry

3. Most common chemotherapy regimens used in combination with bevacizumab30 25 20 15 10 5 29
5-FU bolus 8%
5-FU infusion 60%
Capecitabine 31%
Other 1% 26 18
Patients (%)
Monotherapy Oxaliplatin Irinotecan Other/missing
(15%) (49%) (34%) (1%)
S. Berry

4. Progression-free survival
10.8
n=503
11.6
n=552
11.3
n=346
10.8
n=300
8.6
Median PFS (months)
S. Berry

5. Overall survival 0 10 20 30 Median OS (months) n=1,914 22.7 n=503 23.7
25.9
n=346
23.0
n=300
18.0
Median OS (months)
S. Berry

6. Serious adverse events of special interest for bevacizumab
Any AE or SAE (n=1,914)
CTC grade 3–5 or SAE (n=1,914)
Hypertension
29.9
5.3
Proteinuria
10.4*
1.1
Bleeding
31.0
3.4
Wound-healing complications
4.0
Arterial thromboembolic events
1.5
GI perforation
1.9‡
1.8
*at baseline, 8.9% reported CTC grade 1/2 and 0.2% grade 3/4 proteinuria
‡one patient hospitalised for microperforation
S. Berry

7. Conclusions
The safety and efficacy profile of bevacizumab in this large observational study is consistent with that observed in randomised clinical trials
Bevacizumab can be used safely in combination with any of the commonly used fluorouracil-based first-line chemotherapy regimens
similar benefits are seen with oxaliplatin- and irinotecan-based combinations
Median PFS and OS are consistent with that observed in previous trials of bevacizumab as first-line therapy in metastatic CRC
S. Berry